Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases
| Autor: | Piet Dirix, Peter B. Vermeulen, Charlotte Billiet, C. Mercier, Steven Van Laere, Lieselotte Depuydt, I. Joye, Geert De Kerf, Erik Van de Kelft, Dirk Verellen, Paul Meijnders |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment R895-920 SABR volatility model Article 030218 nuclear medicine & medical imaging Lesion 03 medical and health sciences Medical physics. Medical radiology. Nuclear medicine 0302 clinical medicine Medicine Radiology Nuclear Medicine and imaging Progression-free survival RC254-282 SABR Outcome Toxicity business.industry Spinal instability Neoplasms. Tumors. Oncology. Including cancer and carcinogens Radiation therapy Oncology Spinal metastases 030220 oncology & carcinogenesis Cohort Human medicine Radiology medicine.symptom business |
| Zdroj: | Clinical and Translational Radiation Oncology, Vol 24, Iss, Pp 65-70 (2020) Clinical and Translational Radiation Oncology |
| ISSN: | 2405-6308 |
| Popis: | Highlights • Hypofractionated stereotactic ablative radiotherapy (SABR) in patients with spinal oligometastases. • High rates of efficacy and minimal toxicity. • Oligometastatic patients with metachronous spinal metastases seem to benefit the most. Background To investigate progression free survival (PFS), local control (LC) and overall survival (OS) outcomes for patients treated with spine hypofractionated stereotactic ablative radiotherapy (SABR) and to evaluate possible predictors of rapid progression in view of a correct patient selection for this potentially curative SABR. Materials and methods A cohort of 59 patients with spinal metastases were treated with SABR. Patient selection criteria were the following: histologically proven diagnosis of a solid tumor, a World Health Organization (WHO) score ≤ 2, life expectancy > 6 months, Spinal Instability Neoplastic Score (SINS) ≤ 12 points and presenting with radically treated oligometastatic disease (≤5 lesions) or stable polymetastatic disease with an oligoprogressive lesion. Results From March 2015 to June 2019, 59 patients were treated with Linac-based SABR to 64 spinal metastases with a median follow-up of 55 months. SABR was standard delivered every other day in 3 to 10 fractions with median prescription dose of 27 Gy (range 21–49 Gy). The 1-,2- and 5-year PFS was 98%, 85% and 75% for all patients. OS at 5 years for all patients was 92%. Metachronous lesions (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|